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The hereditary spastic paraplegias are a heterogeneous group of degenerative disorders that are clinically classified as either pure
with predominant lower limb spasticity, or complex where spastic paraplegia is complicated with additional neurological features,
and are inherited in autosomal dominant, autosomal recessive or X-linked patterns. Genetic defects have been identified in over 40
different genes, with more than 70 loci in total. Complex recessive spastic paraplegias have in the past been frequently associated
with mutations in SPG11 (spatacsin), ZFYVE26/SPG15, SPG7 (paraplegin) and a handful of other rare genes, but many cases
remain genetically undefined. The overlap with other neurodegenerative disorders has been implied in a small number of reports,
but not in larger disease series. This deficiency has been largely due to the lack of suitable high throughput techniques to investigate
the genetic basis of disease, but the recent availability of next generation sequencing can facilitate the identification of disease-
causing mutations even in extremely heterogeneous disorders. We investigated a series of 97 index cases with complex spastic
paraplegia referred to a tertiary referral neurology centre in London for diagnosis or management. The mean age of onset was 16
years (range 3 to 39). The SPG11 gene was first analysed, revealing homozygous or compound heterozygous mutations in 30/97
(30.9%) of probands, the largest SPG11 series reported to date, and by far the most common cause of complex spastic paraplegia
in the UK, with severe and progressive clinical features and other neurological manifestations, linked with magnetic resonance
imaging defects. Given the high frequency of SPG11 mutations, we studied the autophagic response to starvation in eight affected
SPG11 cases and control fibroblast cell lines, but in our restricted study we did not observe correlations between disease status
and autophagic or lysosomal markers. In the remaining cases, next generation sequencing was carried out revealing variants in
a number of other known complex spastic paraplegia genes, including five in SPG7 (5/97), four in FA2H (also known as SPG35)
(4/97) and two in ZFYVE26/SPG15. Variants were identified in genes usually associated with pure spastic paraplegia and also in
the Parkinson’s disease-associated gene ATP13A2, neuronal ceroid lipofuscinosis gene TPP1 and the hereditary motor and sensory
neuropathy DNMT1 gene, highlighting the genetic heterogeneity of spastic paraplegia. No plausible genetic cause was identified in
51% of probands, likely indicating the existence of as yet unidentified genes.
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Introduction
The hereditary spastic paraplegias (HSPs) are a diverse group
of neurodegenerative diseases with a prevalence of 2–7.4/
100000 in most populations (Erichsen et al., 2009;
Blackstone, 2012; Noreau et al., 2014). They can be inherited
in autosomal dominant, autosomal recessive or X-linked pat-
terns with an age of onset that varies from early childhood to
70 years of age. HSP was first classified by Harding in the
early 1980s (Harding, 1981), into pure or uncomplicated
HSP, where lower limb spasticity occurs in isolation, fre-
quently with bladder hyperactivity and mild impaired sense
of vibration, and complex HSP that has prominent lower limb
spasticity that is always accompanied by other neurological
finding such as seizures, dementia, amyotrophy, ataxia, deaf-
ness, extrapyramidal disturbance, orthopaedic abnormalities
and peripheral neuropathy (Harding, 1981; Fink, 1993,
2013; Blackstone et al., 2011; Finsterer et al., 2012).
Mutations in over 40 genes have been found to cause
HSP (de Bot et al., 2010, 2012; Dufke et al., 2012;
Coutinho et al., 2013; Denora et al., 2013; Loureiro
et al., 2013; Novarino et al., 2014). The most common
cause of autosomal dominant spastic paraplegia are
SPAST/SPG4 mutations, with patients presenting with a
pure form of HSP (Schule and Schols, 2011; Finsterer
et al., 2012; Fink, 2014; Noreau et al., 2014).
In the autosomal recessive complex HSP, the most fre-
quent form seems to be associated with thinning of the
corpus callosum (Boukhris et al., 2008; Finsterer et al.,
2012) and it is mostly due to mutations in SPG11
(Stevanin et al., 2007; Paisan-Ruiz et al., 2008a, 2010b;
Schule and Schols, 2011). It is also important to assess
patients for rare causes of complex HSP such as enzyme
deficiencies either biochemically or genetically (Wu et al.,
2015). SPG11 is clinically characterized by slowly
progressive spastic paraplegia and cognitive decline usually
beginning before the second decade of life. Four less
common distinct phenotypes have also been associated
with SPG11 mutations, including Kjellin syndrome, which
is a rare form of HSP with additional retinal manifestations
(Puech et al., 2011; Nowak et al., 2014), slowly progressive
amyotrophic lateral sclerosis (Orlacchio et al., 2010;
Daoud et al., 2012), syndromes reminiscent of dystonia-
parkinsonism (Paisan-Ruiz et al., 2010b; Kara et al.,
2013) and syndromes with prominent L-DOPA responsive
parkinsonism (Anheim et al., 2009a; Everett et al., 2012a).
There have been reports of other types of spastic paraplegia
being associated with improvement with L-DOPA (Mallaret
et al., 2014). The increasing heterogeneity of spastic para-
plegia and the clinical overlap seen with several other con-
ditions suggests that there is still considerable genetic
expansion to come in this group of disorders (Beetz
et al., 2008; de Bot et al., 2012).
The clinical heterogeneity of HSP reflects the contribution
of diverse cellular pathways to their pathogenesis (Crosby
and Proukakis, 2002; Salinas et al., 2008; Blackstone et al.,
2011). A number of proteins and pathways have been
implicated including mitochondrial dysfunction (HSP60,
spartin, paraplegin), microtubule trafficking and other
membrane trafficking pathways (spastin, REEP1, atlsatin),
lysosomal dysfunction (ZFYVE26), macroautophagy (spa-
tacsin, ZFYVE26, AP5Z1) and lipid metabolism (FA2H,
CYP7B1) (Salinas et al., 2008; Blackstone, 2012). The iden-
tification of macroautophagy is of particular interest, as
autophagic dysfunction has been implicated in the patho-
genesis of HSP (Chang et al., 2014), but also in a number
of other neurodegenerative diseases such as Parkinson’s
disease, Alzheimer’s disease, Huntington’s disease and
the spinocerebellar ataxias (Nixon, 2013). Given this mech-
anistic overlap and the presence of spasticity in other
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neurodegenerative and movement disorder phenotypes,
defects in these genetic pathways are likely to overlap,
particularly within processes involved in mitochondrial
functions (Schapira, 1999).
The aim of this study was 3-fold. First, to study the geno-
type–phenotype correlations and clinical features seen in a
series of complex spastic paraplegia. We particularly
focussed on SPG11, which makes up by far the largest
group of complex spastic paraplegia cases. Second, to
assess whether variants in genes that cause pure HSP, and
other movement and neurodegenerative disorders are also
involved in complex HSP. Third, following the identification
of SPG11 mutations as the most common cause of compli-
cated spastic paraplegia, we investigated spatacsin (the pro-
tein product of SPG11) through biochemical studies in a
series of fibroblasts taken from patients and controls.
Materials and methods
Patients
A cohort of 97 patients that were referred to the National
Hospital for Neurology and Neurosurgery (NHNN) for inves-
tigation or diagnosis were included in this study. Institutional
review board (IRB)/ethical approval (UCLP – 99n102) and
consent were obtained. We enrolled complex HSP patients
and families where clinical details and DNA samples were
available at the NHNN prior to 2015. From each family, we
included only the proband. The inclusion criteria were slowly
progressive HSP as the earliest manifestation or as the most
significant clinical finding or the clinical reason for referral,
along with at least one additional neurological feature such
as: peripheral neuropathy, cognitive decline, epilepsy, skel-
etal/bony abnormalities, visual problems, parkinsonism, dys-
tonia and ataxia (Fink, 1993, 2014). Nerve biopsy was
carried out on one case and muscle biopsies on five cases
(Houlden et al., 2001). Acquired or metabolic causes of HSP
were excluded with an investigative work-up of MRI of the
brain and spine, long chain fatty acids, white cell enzymes,
routine and special blood tests for human T-lymphotropic
virus (HTLV), Venereal Disease Research Laboratory test
(VDRL), anti-nuclear antibodies (ANA)/extra nuclear antibo-
dies (ENA)/anti-neutrophil cytoplasmic antibodies (ANCA),
lupus and electromyography (EMG)/nerve conduction studies
(NCS) and somatosensory evoked potentials (SSEP)/visual
evoked potentials (VEP)/auditory evoked potentials (AEP)
often early in the diagnosis. When referring to overall severity
of clinical signs we used mild, moderate, and severe. An ex-
ample of this classification is with urinary problems where
mild signs would be untreated urgency or frequency symp-
toms, moderate as therapeutically treated symptoms, and
severe when a long-term catheter of different types is required.
The overall degree of disability severity was measured with the
modified Rankin score where mild is52.0, moderate is 2.5–
3.5 and severe54. This scale is used for measuring the degree
of disability in the daily activities of people who have suffered
any causes of neurological disability. The scale runs from 0–6,
ranging from perfect health without symptoms to death
(Bonita and Beaglehole, 1988).
Sanger sequencing
Sanger sequencing of the entire coding region of SPG11 was
carried out as previously described (Stevanin et al., 2007).
Primer sequences and conditions are listed in Supplementary
Tables 4 and 5. When a mutation was identified in a familial
case, DNA samples from available family members were also
analysed by Sanger sequencing to assess segregation and to
determine the phase in cases with compound heterozygous
mutations (Table 1 and Supplementary Table 1). SPG11 mu-
tations were named following the transcript NM_025137.3.
For one case (Case 52) in which SPG11 was negative for mu-
tations, subsequent homozygosity mapping indicated FA2H as
a candidate gene, which was found to be defective in this
family. Multiplex ligation-dependent probe amplification
(MLPA) was carried out using probes for SPG11 [P306 kit
(MRC Holland)] in 42 patients negative for mutations in
SPG11. A sample was considered negative when all probes
were within 0.75–1.25 copies and standard quality control
criteria were met. Variants identified using next generation
sequencing were also confirmed through Sanger sequencing.
Next generation sequencing
A total of 66 patients were analysed that were either Sanger
negative for SPG11 mutations, carried a single heterozygous
mutation or were more recently identified cases. These were
analysed using either the Illumina next generation clinical
exome (Trusight one) sequencing (Illumina Inc) targeting
4813 genes where target genetic regions were covered at
least 30 in over 99% of the regions analysed, and seven pa-
tients underwent diagnostic Illumina whole exome sequencing,
where coverage of the targeted genes was high though the
Trusight clinical exome was superior. For data analysis, the
raw data were mapped to the hg19 human reference assembly
using the NovoAlign software, and polymerase chain reaction
(PCR) duplicates were removed using the Picard software.
Insertions-deletions (indels) and single nucleotide variants
were called using the GATK package or SAMtools, and vari-
ants annotated using ANNOVAR, as previously described
(Hersheson et al., 2013). In the preliminary filtering, variants
with a minor allele frequency over 1/1000 in dbSNP (http://
www.ncbi.nlm.nih.gov/snp/) or in the ExAC database (http://
exac.broadinstitute.org/), synonymous variants and variants
that were present in a segmental duplication region of over
95% were excluded. We focused on a subset of genes in
which mutations have been previously associated with spastic
paraplegia, neurodegeneration, ataxia, peripheral neuropathy,
Parkinson’s disease and pallidopyramidal syndromes. Except
in Case 48 where DNA was not available for Sanger, probable
variants were confirmed through Sanger sequencing and were
assessed for segregation in other affected or unaffected family
members.
Studies on patient-derived fibroblasts
Skin biopsies were obtained from eight affected patients with
homozygous or compound heterozygous mutations in SPG11
and nine healthy control subjects. Cases and controls were
matched by gender, age and passage number (indicating the
number of times a particular cell line has been subcultured and
is used as a proxy for the age of the cells in culture) to the
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extent possible. Details of the cell lines used in this study are
summarized in Supplementary Table 6. Fibroblasts were
grown as previously described (Tucci et al., 2014) and reverse
transcriptase PCR was used to assess the transcription of
SPG11 in fibroblast cell lines (Cottenie et al., 2014). Primers
spanning exons 7–8 of SPG11 were designed to avoid non-
specific amplification of genomic DNA. GAPDH was used as a
housekeeping gene (see Supplementary Tables 4 and 5 for
primer sequences and conditions). Autophagy was assessed
through western blot analysis of autophagy and lysosomal
markers including LAMP1, LC3, p62, HSP70 as previously
described (Manzoni et al., 2013) (Supplementary material).
LAMP1 is a structural component of lysosomes and conse-
quently it can be used as a marker for lysosomal size and
number. LC3-II is considered a marker for macroautophagy
(Tanida et al., 2008). p62 is a cargo protein that binds to
proteins targeted to autophagosomes for degradation
(Mizushima and Komatsu, 2011). The HSP70 family of pro-
teins, in particular Hsc70, participate in chaperone-mediated
autophagy promoting internalization of targeted proteins in
lysosomes through LAMP2A (Agarraberes et al., 1997).
Among the substrates of mTOR phosphorylation, we selected
P70S6K as a marker of efficient starvation. The phosphory-
lated form of P70S6K decreases during starvation and can be
used as a marker for the efficiency of the starvation experi-
ments. P70S6K is a phosphorylation substrate only for mTOR
(Nixon, 2013) and is thus specific to check for mTOR block
by starvation. Each experiment was repeated at least three
times.
Results
Genetic findings
A likely pathogenic genetic defect was identified in 48/97
(49%) of complex HSP patients (Fig. 1A, Table 1 and
Supplementary Table 1). This does not include variants of
unknown significance. Homozygous or compound hetero-
zygous mutations in SPG11 were identified in 30.9% of
patients (30/97), which is the largest series to date and
the most common cause of disease in complex HSP in the
UK (Fig. 1D). No cases carrying copy number variants
within the SPG11 locus were identified using MLPA. The
vast majority of SPG11 mutations were non-sense or
frameshift changes. Interestingly no homozygous mutations
are present in the ExAC database (http://exac.broadinsti-
tute.org/gene) of over 100 000 control population cases,
indicating that loss of function mutations are not tolerated
in the general population. SPG11 was followed by SPG7
(5/97), FA2H/SPG35 (4/97), ZFYVE26/SPG15 (2/97) and
single families with SPG3a (ATL1), SPG8 (KIAA0196),
SACS and SPG5 (CYP7B1) (Fig. 1A). Variants within
genes associated with Parkinson’s disease (PARK9;
ATP13A2), neuronal ceroid lipofuscinosis (NCL; TPP1)
and hereditary neuropathy (DNMT1) were also identified.
From the variants identified, nine in SPG11, and one in
FA2H and one in KIAA0196 had been previously reported
(Paisan-Ruiz et al., 2008a, b, 2010b; Dick et al., 2010;
Everett et al., 2012a; Bettencourt et al., 2013; Nowak
et al., 2014). Variants in other non-SPG11 genes were
not found in the ExAC population control database at a
frequency of510 heterozygous cases, except for Cases 38,
39, 44 and 48. Case 48 carries two CYP7B1 likely com-
pound heterozygous variants, where one (p.R486C) is re-
ported as pathogenic (Goizet et al., 2009) and present in 82
ExAC population individuals and the other variant
(c.122 + 2T4C) is absent in this dataset. Cases 38, 39
and 44 carry the SPG7 variant p.A510V, which was pre-
sent in 57 individuals on the ExAC database but has pre-
viously been multiply-reported as pathogenic (Choquet
et al., 2015; Pfeffer et al., 2015). In addition, the SPG7
variants we identified and those previously reported, often
had a similar phenotype of spastic ataxia but we also high-
light the prominent opthalmoplegia (Choquet et al., 2015).
Variants of unknown significance were also identified
(Supplementary Table 3) and are discussed in detail in
the Supplemental material and a summary of the negative
case details is given in Supplementary Fig. 3.
Clinical findings
In the 97 individuals identified with complex HSP, the clin-
ical phenotypes primarily consisted of HSP with ataxia as
the most common association, followed by cognitive de-
cline, neuropathy, seizures, dystonia, parkinsonism and
rarely other features. The mean age of onset was 16
years, ranging from age 3 to 39 years. Summary clinical
information for the complex HSP cases is given in Table 1
and Supplementary Tables 1–3.
SPG11
General features
SPG11 mutations were identified in 30 probands. We
removed one proband that may be distantly related to
Family 6 because they come from the same ethnic commu-
nity group and have the same mutation. In general, SPG11
onset was in childhood/early teenage years (mean age at
onset 14.3 years, range 4–27 years), with walking problems
and spasticity, severe bladder problems, ataxia, neur-
opathy, parkinsonism and/or cognitive problems (Table 1
and Fig. 1B).
Atypical presentation
Some patients presented in an atypical way, such as the
proband from Family 5 (Table 1) who exhibited a very
mild phenotype including toe walking, brisk reflexes and
extensor plantars at the age of 12 years with little disease
progression by the age of 22 years. His aunt had typical
SPG11 features in her 30s. Case 10 had spastic paraplegia
with severe optic atrophy and visual problems. The pro-
band from Family 6 had a severe and treatment-resistant
oromandibular dystonia. Interestingly his sister had a rela-
tively mild phenotype but his distant community cousins
had a typical severe SPG11. The longest surviving case
1908 | BRAIN 2016: 139; 1904–1918 E. Kara et al.
carrying an SPG11 mutation is currently 50 years of age
and has severe complex HSP as well as severe cognitive
decline and late-onset seizures, similar to the deceased sib-
ling (Family 25).
Genotype–phenotype correlations
There were no clear genotype–phenotype correlations that
we could define although Case 5 with the mildest clinical
and MRI phenotype had a homozygous missense mutation,
and progressed relatively slowly.
MRI findings
The MRI findings in SPG11 patients are presented in
Fig. 2A; images were compared to controls. Patients
with mild-to-moderate disease had minimal corpus callo-
sum thinning while severe SPG11 patients had more
severe thinning as well as cerebral atrophy. When the dis-
ease is severe the corpus callosum remains at a static state
and does not seem to change over time, as in
Supplementary Fig. 1, although these are longitudinal
data from only two cases.
SPG11 (30/31%)
SPG7 (5/5%)
FA2H (4/4%)
ZFYVE26 (2/2%)
DNMT1 (1/1%)
ATP13A2 (1/1%)
CYP7B1 (1/1%)
TPP1 (1/1%)
ATL1 (1/1%)
KIAA0196 (1/1%)
SACS (1/1%)
No gene (49/51%)
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Figure 1 Overview of mutations identified in spastic paraplegia genes. (A) Pie chart showing the frequency of mutations in spastic
paraplegia genes identified. The figures in brackets represent the number and percentage of cases respectively. (B) Frequencies of clinical features
that were present in addition to the spastic paraplegia in SPG11 probands. (C) Frequencies of clinical features that were present in addition to
spastic paraplegia in the spastic paraplegia patients with other mutations. In B and C the figures in brackets refer to the number of cases. (D)
Diagram of the SPG11 gene with mutations identified in the present study. Grey arrows indicate novel and black arrows indicate previously
reported mutations.
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Figure 2 MRI features in patients with complex HSP. (A) Sagittal MRI of SPG11 patients showing progressive thinning of the corpus
callosum and cerebral atrophy, which correlates with the progression of clinical features. (i) MRI from a healthy individual with labelling of the
different parts of the corpus callosum. (ii) Case 5 at age 18 (mild disease). (iii) Case 8 at age 22 (mild-moderate disease). (iv) Case 17 at age 23
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SPG7
General features
Five families were identified with SPG7 variants (Families
35, 37–39 and 44). In the Kenyan family (Family 35), pres-
entation was in the 30s with progressive spasticity and
ataxia. In the other families, disease onset was earlier,
often with an initial diagnosis of cerebral palsy or poor
coordination. Associations of SPG7 variants with optic at-
rophy, neuropathy and ophthalmoplegia were also
identified.
SPG35 (FA2H)
General features
Four families with FA2H (SPG35) variants were identified
(Families 32, 34, 51 and 52; Supplementary Table 1), of
which three carried compound heterozygous variants and
one a homozygous variant. In Families 32, 51 and 52 seg-
regation was shown in affected and unaffected members.
The age of onset varied between 5 and 22 years with the
initial presentation being progressive balance problems and
toe walking. Spastic quadriplegia was present on examin-
ation, along with early bladder problems, dysarthria, dys-
phagia and limb ataxia. One family had severe
ophthalmoplegia and skew defect, seizures were present in
two families, and two families had optic atrophy.
Interestingly, the dysarthria progressed rapidly in all
cases, developing into an early anarthria which is different
than SPG11 and 15 and an important clinical point to
note.
MRI findings
MRI findings ranged from atrophy of the cerebellum and
brain stem to more significant findings that also included
corpus callosum atrophy, cortical atrophy and white matter
abnormalities (Fig. 2C).
ZFYVE26/SPG15
General features
Two cases with homozygous mutations in ZFYVE26/
SPG15 were identified. These cases presented and pro-
gressed in a very similar way to SPG11, although the neur-
opathy was greater (Supplementary Table 1 and Figs 2B
and 4). In the non-SPG11 cases there were also additional
neurological features, as shown in Fig. 1C.
Atypical presentation
In addition, Case 33 has adducted thumbs that were very
similar to those seen in mental retardation, aphasia, shuf-
fling gait, and adducted thumbs (MASA) syndrome (SPG1),
an X-linked spastic paraplegia syndrome that is caused by
mutations in the LICAM gene (Jouet et al., 1994; Vits
et al., 1994) (Fig. 3).
Figure 2 Continued
(moderate disease). (v) Case 10 at age 30 (severe disease). (vi) Case 16 age 32 (severe disease). (vii) Case 9 age 39 (severe disease). See Table 1
for details of case numbers. (B) MRI of complex HSP cases. (i) Case 37 (age 24 years), SPG7 showing an axial MRI with high signal in the cerebral
peduncles (arrow) and on coronal imaging (ii) and sagittal imaging (arrow) (iii) with thinning of the body of the corpus callosum (arrow). Case 33
(age 34 years) (iv to vi), SPG15 with thinning of the corpus callosum (iv) (arrow) and generalized atrophy with periventicular white matter
abnormalities (arrow). (C) Sagittal MRI of FA2H patients. (i–iii) Case 32, age 32 years, slowly progressive with thinning of the corpus callosum,
cerebellar and cortical atrophy. (iv–vi) Case 52, age 37 years, more rapid and severely affected: shows severe corpus callosum thinning, cerebellar
and cerebral atrophy, but preserved white matter, similar to the Case 32.
Figure 3 Photographs of the hands of Case 33 with ZFYVE26/SPG15 mutation (homozygous p.R1378* mutation). Showing the
adducted thumbs that are similar to those seen in MASA (mental retardation, aphasia, shuffling gait and adducted thumbs) syndrome. Age of
patient: 34 years.
Characterization of complex hereditary SPG BRAIN 2016: 139; 1904–1918 | 1911
ATP13A2
General features
The proband from Family 41 presented at 18 years old
with spastic quadraplegia, falls, cognitive decline, bilateral
pes cavus and ataxia. Eye signs were prominent, with bi-
lateral divergent squints and nystagmus on lateral gaze and
reduced upgaze. He was the product of a consanguineous
marriage. Genetic testing revealed novel heterozygous vari-
ants in ATP13A2 (c.3017_3019del; p.1006_1007del),
which are near/in the transmembrane helix and not present
in over 100 000 ExAC controls.
MRI findings
The MRI showed cerebral atrophy and subtle abnormalities
of the basal ganglia. An L-DOPA trial initially helped pa-
tient symptoms but there were no signs of objective or
long-term improvement.
TPP1
General features
In Family 43, which was found to carry a variant in TPP1,
the proband initially presented with walking problems, pro-
gressive spastic paraplegia and poor intellectual function at
the age of 11 years old, with a past history of two seizures.
At the age of 31 she had severe spasticity in her limbs,
along with a bulbar palsy, dystonic neck posturing and
also severe cognitive problems. There is no family history.
MRI and additional tests
Her MRI showed cerebral atrophy and thinning of the
corpus callosum (Supplementary Fig. 1). There were back-
ground EEG abnormalities but the muscle and skin biopsy
was normal. She responded to L-DOPA for 5 years that
improved her mobility temporarily, though screening for
variants in GCH1 was negative.
Nerve conduction studies, EMG and
nerve biopsy
Nerve conduction studies and EMG were minimally helpful
in defining some types of HSP (Supplementary Table 2).
One SPG11 case was abnormal along with both
ZFYVE26/SPG15 cases. Similarly, a nerve biopsy was
also abnormal in ZFYVE26/SPG15 [Case 33, Fig. 2B(iv–
vi)].
Characterization of the autophagic
response in SPG11 patient-derived
fibroblasts
Reverse transcription PCR on RNA extracted from fibro-
blast cell lines from cases and controls showed that SPG11
is expressed in this tissue at levels similar to the housekeep-
ing gene GAPDH (Fig. 5). We studied the different
autophagy and lysosomal markers in fibroblasts under
basal conditions (Supplementary Figs 4–7) and after induc-
tion of autophagy by starvation (Fig. 6A and B, and
Supplementary Figs 4–7). We did not observe significant
correlations between disease status and autophagic/lyso-
somal markers, although there was a trend towards
increased LC3-II in cases.
Discussion
Here we describe the genetic analysis of 97 complex HSP
probands using a combination of Sanger and next gener-
ation sequencing. We identified the genetic cause of the
disease in 49% of the patients studied. SPG11 defects
were found to be by far the commonest cause of complex
HSP in the UK, accounting for 30.9% of cases and being
the largest series reported to date. This is higher than pre-
vious reports (Stevanin et al., 2007, 2008; Erichsen et al.,
2008; Paisan-Ruiz et al., 2008a; Anheim et al., 2009a;
Orlen et al., 2009; Schule et al., 2009; Orlacchio et al.,
2010; Southgate et al., 2010; Guidubaldi et al., 2011;
Daoud et al., 2012; Cao et al., 2013), but the frequency
is in-line with a recent study from Italy (26.2%) (Pensato
et al., 2014). Variants in SPG7 represented 6% and the
frequency of FA2H was also higher that previous reports
at 4% (Pensato et al, 2014). ZFYVE26/SPG15 was infre-
quent in our cohort with only two families although Family
33 extends the clinical features associated with variants in
this gene (Figs 3 and 4). The discrepancy in the variants
frequency is likely population-specific and possibly due to
the use of next generation sequencing in our report, in
contrast to previous candidate gene-based studies. In add-
ition, our cohort was a multi-ethnic population, whereas
those in previous reports were ethnically more homoge-
neous, focusing on the Mediterranean basin or Caucasian
populations.
The core clinical presentation of SPG11 was consistent
with previous reports, but a number of other neurological
features were identified (Fig. 1B). The age of onset ranged
between 4 and 27 years, most frequently presenting with
walking problems due to lower limb spasticity and later
ataxia and foot deformities. Other progressive neurological
features include parkinsonism that often responded
to L-DOPA, axonal neuropathy and learning difficulties
(Fig. 1B). In addition SPG11 cases tended to remain
mobile up until 30 years, with a mean modified Rankin
score of53. Patients aged over 30 years were more signifi-
cantly disabled and completely dependent when over 40
years (Supplementary Fig. 2) (Patel et al., 2012).
One SPG11 patient with extreme visual problems was
found to have Kjellin syndrome, although optic atrophy
and retinal signs were generally rare in this HSP (Puech
et al., 2011; Nowak et al., 2014). The majority of patients
had white matter abnormalities and corpus callosum thinning
on MRI, though this feature was not restricted to SPG11
mutations as we also observed it in ZFYVE26/SPG15 and
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Figure 4 Morphological findings of one nerve and four muscle biopsies in five genetically characterized patients with HSP.
Patient with ZFYVE26/SPG15 mutation (A and C) and control individual (B and D). SPG11 mutation (E), SPG7 mutation (F and G). Semi-thin resin
preparations stained with methylene blue azure—basic fuchsin (A and B) show a reduction of large myelinated fibre density in the patient’s biopsy,
compared with a biopsy from age-matched control. Large fibre loss is further confirmed by electron microscopy (C and D), while unmyelinated
fibres are better preserved. There is no evidence of active axonal degeneration, regeneration or demyelination and the overall picture is that of
chronic axonal neuropathy. The muscle biopsies from three patients investigated for signs of denervation show varied appearances. In the biopsy
from the patient with a known SPG11 mutation (E) there is predominance of type 1 fibres (yellow arrow, ATP pH4.3). In one patient with SPG7
mutation (F) the most significant finding in the muscle biopsy is that of several COX-deficient fibres (red arrows) seen on combined COX-SDH
preparation. In another patient with SPG7 mutation (G) the biopsy confirms neurogenic change with evidence of previous denervation with re-
innervation (blue arrow indicates a group of type 1 fibres, ATP pH4.3). Scale bars: A, B and E–H = 40mm; C and D = 5 mm.
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FA2H variant carriers (Fig. 2A–C). Although in a relatively
low number of patients, SPG11 was associated with parkin-
sonism in five cases and was L-DOPA-responsive in three
cases, indicating a role for the basal ganglia in HSP, suggest-
ing that this medication should be considered in SPG11-asso-
ciated HSP. Two patients had a positive family history of
essential tremor (Case 6) and Parkinson’s disease (Case 15),
an observation that has previously been made in other
families (Kang et al., 2004; Anheim et al., 2009b; Paisan-
Ruiz et al., 2010a; Guidubaldi et al., 2011; Everett et al.,
2012b). Other clinical features that we found in patients with
SPG11 mutations include telangiectasia (Case 9) and bilateral
cataracts (Case 21). We did not observe a predilection for
males in comparison to females; thus, gender-specific factors
are not likely to contribute to the pathogenesis of SPG11
mutations, contrary to other genetic forms of HSP
(Proukakis et al., 2011).
A number of the mutations identified within SPG11 were
previously undescribed. The majority of these mutations
were nonsense, distributed throughout the coding length
of the gene, supporting a loss-of-function mechanism
underlying disease. One family with mild disease was
found to carry a previously reported homozygous missense
mutation p.V1270D (Case 5) (Conceicao Pereira et al.,
2012) altering a highly conserved residue and segregating
with disease, and this may suggest that missense mutations
lead to a milder phenotype although certainly more cases
are required to prove this. No patients carried larger gen-
omic rearrangements and similarly, previous studies have
only very rarely identified such mutations within SPG11
(Bauer et al., 2009; Crimella et al., 2009; Denora et al.,
2009; Conceicao Pereira et al., 2012).
In our cohort, FA2H variants were associated with a
spectrum of disability ranging from mild through to se-
verely affected. In all four families, affected members ex-
hibited dysarthria that rapidly progressed to anarthria,
which is a feature that could be used as a diagnostic clue
to initiate genetic testing for FA2H variants. Interestingly,
FA2H variants have been previously associated with neu-
rodegeneration with brain iron accumulation (Kruer et al.,
1993, 2010). It is unknown what factors could influence
the development of iron accumulation in the brain in asso-
ciation with this variant. A number of unusual HSP asso-
ciations were identified with variants in genes such as
DNMT1, ATP13A2 and TPP1, which warrants wider gen-
etic testing of complex HSP, with SPG11 being the first
candidate, followed by the other three genes (FA2H,
SPG7, ZFYVE26/SPG15).
The patient with the ATP13A2 variant had a progressive
HSP with ataxia and cognitive problems but no parkinso-
nian features seen and the patient with TPP1 variants had a
complex HSP that was considered likely to be SPG11. In
this case SPG11 was Sanger sequenced several times and
deletion analysis carried out until the TPP1 variant was
identified. Variants in TPP1 and ATP13A2 have been pre-
viously identified in patients with NCL although not with a
HSP phenotype (Schnabel et al., 1991; Sleat et al., 1997;
Bras et al., 2012). ATP13A2 variants are associated with
heterogeneous phenotypes including Kufor-Rakeb syn-
drome (Ramirez et al., 2006), NCL (Bras et al., 2012)
and Parkinson’s disease (Malakouti-Nejad et al., 2014).
Kufor-Rakeb syndrome clinically partially overlaps with
HSP as patients often exhibit spasticity in addition to dys-
tonia, parkinsonism and mental retardation (Ramirez et al.,
2006). Patients with NCL caused by ATP13A2 variants
have similar clinical features with Kufor-Rakeb syndrome
patients (Bras et al., 2012). NCL syndromes are character-
ized by accumulation of autofluorescent material, a feature
that is not characteristic of HSP, though biopsy material
was not as yet available for our HSP patient with the
ATP13A2 variant. In general, these findings suggest an
overlap between spastic paraplegias and numerous other
neurodegenerative diseases, an observation that has already
been made through protein network analyses (Novarino
et al., 2014). Our results also highlight the worldwide dis-
tribution of mutations in genes associated with autosomal
recessive spastic paraplegias and these data indicate that
ethnic background should not be a criterion to prioritize
patients for genetic testing. These findings expand the clin-
ical spectrum of complex spastic paraplegias and underline
the clinical overlap with other diseases such as spinocere-
bellar ataxias and dystonia-parkinsonism and the difficulty
of prioritizing genetic testing in these patients where func-
tional investigation should ideally be applied to all likely
pathogenic variants. Thus, the use of next generation
sequencing-based panels containing a series of candidate
genes is becoming exceedingly important in the genetic
work-up of such patients.
Numerous variants of unknown significance were de-
tected, which is a common problem associated with the
application of high throughput approaches to study the
genetic basis of diseases (MacArthur et al., 2014). These
cases could represent a broadening of the clinical pheno-
type but future studies are necessary to clarify this. We did
not identify definite or probable variants in any of the
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Figure 5 Reverse transcription PCR to assess SPG11
mRNA expression in fibroblasts. Wide expression is seen
across SPG11 affected and control fibroblasts. Numbers in red are
SPG11 affected cases from Table 1 and Supplementary Table 1.
Letters in blue are controls from Supplementary Table 1.
GAPDH = housekeeping gene glyceraldehyde 3-phosphate
dehydrogenase.
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Figure 6 Analysis of markers for autophagy and lysosomal function in human fibroblast cells. (A) Fibroblast protein expression
levels of LAMP1 and LC3 as compared to beta actin in SPG11 affected and control fibroblasts after starvation induced autophagy (overnight serum
starvation, followed by 2.5 h amino acid starvation in low glucose). (B) Fibroblast protein expression levels of p62 and HSP70 as compared to beta
actin in SPG11 affected and control fibroblasts after starvation induced autophagy (overnight serum starvation, followed by 2.5 h amino acid
starvation in low glucose).
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genes studied in 51% of the cases. This observation indi-
cates that there are probably additional rare variants in
novel genes causing spastic paraplegia that have not yet
been discovered. Alternatively, it is possible that other
types of genetic mechanisms such as mosaicism
(Proukakis et al., 2013), di- or polygenic inheritance and
imprinting defects could be responsible for the disease in a
proportion of patients.
The functional role of spatacsin is unknown, though can-
didate gene pathway analysis has implicated autophagic
dysfunction in the pathogenesis of the disease (Chang
et al., 2014). We attempted to replicate previous findings
linking spatacsin with the regulation of autophagy using a
cohort of patient-derived fibroblasts. Although a trend to-
wards an increase in LC3-II was present in cases, no sig-
nificant changes in autophagy markers of disease were
identified in these cells under the experimental conditions
used herein to assess autophagy. It should be noted, how-
ever, that interpretation of results from functional studies
on patient fibroblasts requires caution, as interindividual
variability is an important limitation that could potentially
mask real effects of mutations or, alternatively, lead to false
positives. Further studies with an increased number of cases
and controls are therefore required to determine whether
spatacsin has a role in the regulation of autophagy, includ-
ing detailed analysis of autophagic flux following treatment
with bafilomycin. Such functional characterization of spa-
tacsin will be crucial to understanding the mechanisms
underlying degeneration in these cases, as well as develop-
ing potential therapies. While outside the scope of this pre-
sent study, this should be a priority for the research
community in the future.
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